This expert panel will review how to improve patient outcomes by managing presbyopia-correcting intraocular lenses (IOLs) in today’s optometric practice. This 1-hour program will review how to match patients with the appropriate IOL and optimize their outcomes. Program content will include evidence-based didactic presentations, interactive panel discussions, and relevant case presentation discussions.
Supported by unrestricted educational grants from Alcon, Carl Zeiss Meditec, Inc., Glaukos, and Johnson & Johnson Vision.Comanaging Premium IOL Patients: Astigmatism Correction
Learning Objectives
After completing this educational activity, participants should be better able to: - Describe and identify current and emerging astigmatism correcting IOLs:
- Risks and benefits of each
- Patient selection/exclusion criteria
- Patient expectation management
- Describe elements of a standardized postoperative outcomes assessment for patients with astigmatism correcting IOLs
- Cite literature on the impact of rotational error on the quality of vision and patient satisfaction in toric IOL patients
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity. The following faculty/staff members have the following financial relationships with commercial interests: Douglas K. Devries, OD, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant and Speakers Bureau: Alcon, Bausch + Health, Bio Tissue, Dompe, EyeVance, Johnson & Johnson Vision, Lumeris, Novartis, OcuSoft, Sun, and TearLab, Share/Stockholder: RPS Marc Bloomenstein, OD, FAAO, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Alcon, Allergan, Bausch + Lomb, Johnson & Johnson Vision, Novartis, OcuSOFT, Reichert and Sun. Speaker’s Bureau: Alcon, Allergan, Bausch + Lomb, Johnson & Johnson Vision, Novartis, and Sun. Research/Grant Support: Allergan. Stock/Shareholder: TearLab. Editorial Support Disclosures Erin K. Fletcher, MIT, director of compliance and education; Evolve; and Kate Fehlhaber, PhD, writer, have no financial relationships with commercial interests.
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.Disclaimer
OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Alcon, Carl Zeiss Meditec, Inc., Glaukos, and Johnson & Johnson Vision. System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!

































